We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

GP Nutrition

Status: Expired

Oct 7th 2019 - Nov 6th 2019

GP Nutrition is a nutrition company that creates products meant to deliver sustainable weight loss. This award-winning company was created by Gabriela Peacock, a celebrity nutritionist. It has 13,000 global customers who have bought more than 30,000 packs. In June'19, the company reached trading of £50k per month. It has produced 22 products that are now sold in 30 countries. GP Nutrition has delivered revenue of £377k and an EBITDA of £813,389. Nutrition's vision is to solve the 95% failure rate of diets in the USA and the UK.

read more read less
Log in to view amount pledged

    Log in to view target

    £4,000,000
    pre-money valuation

    11.11%
    equity available

    77
    investors

    £4,025
    pledge per investor

    09044199
    company number

    Active
    company status

    16/05/2014
    incorporated 10 years

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    01 May 24 Crowdcube £309,890 / 62%

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld

Log in to view amount pledged

    Log in to view target

    £4,000,000
    pre-money valuation

    11.11%
    equity available

    77
    investors

    £4,025
    pledge per investor

    09044199
    company number

    Active
    company status

    16/05/2014
    incorporated 10 years

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    01 May 24 Crowdcube £309,890 / 62%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph